Engineering the Medicines of Tomorrow · Compelling primary analysis data Study ongoing with responding patients Chemo-free regimen Phase 2/3, randomized, multicenter trial Biomarker

1© MorphoSys AG | Meet the Team | June 25, 2019

Engineering the Medicines of Tomorrow

Simon Moroney, Chief Executive Officer

Meet the Team | June 25, 2019


This presentation includes forward-looking statements.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2019,

the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product

candidates of its collaborators, the development of commercial capabilities, in particular with respect to tafasitamab (MOR208) and the transition of

MorphoSys to a fully integrated biopharmaceutical company, interaction with regulators, including the potential approval of MorphoSys’s current or future

drug candidates, including discussions with the FDA regarding the potential approval to market tafasitamab, the expected time of launch of tafasitamab,

and expected royalty and milestone payments in connection with MorphoSys’s collaborations. The forward-looking statements contained herein represent

the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results,

financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future

results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if

MorphoSys’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such

forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are

that MorphoSys’s expectations regarding its 2019 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs

may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory

approval requirements (including that MorphoSys may fail to obtain regulatory approval for tafasitamab and that data from MorphoSys’s ongoing clinical

research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys’s

reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors

included in MorphoSys’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the

reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of

publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any

change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may

affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or

regulation.

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently

approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for

guselkumab/Tremfya®). Any shown cross-trial comparison between MorphoSys-own investigational products and literature data have significant

limitations. Such data comparisons have been prepared at the request of, and for the sole benefit of, the investor community.

3

Effective on September 1, 2019

© MorphoSys AG | Meet the Team | June 25, 2019

New CEO Dr. Jean-Paul Kress

Over 20 years in the pharmaceutical and

biotechnology industry, with a strong track record

of commercial and operational leadership in North

America and Europe

Prior senior management roles include

Syntimmune: Chief Executive Officer

Biogen: Executive Vice President and Head of

Global Therapeutic Operations

Sanofi: Senior Vice President, Head of North

America at Sanofi Genzyme

Sanofi Pasteur MSD: President, CEO

Gilead: General Manager, France, and member

of the operating committee

Eli Lilly and Abbvie: Product management

M.D. degree from Faculté Necker-Enfants Malades

(Paris)

Graduate and post-graduate degrees in

pharmacology and immunology from École Normale

Supérieure (Paris)

4

Develop the medicines of tomorrow to improve the lives of patients

suffering from serious diseases


Our Mission


We are at an inflection point on the way to becoming

a fully integrated biopharmaceutical company

6

Leveraging our clinical assets to anchor a new growth trajectory


Strong Clinical Pipeline

Segment revenues

2018

Partnered Discovery

23 clinical candidates

25 programs in preclinic

58 programs in discovery

Valu

e

Business transformation

~€54 million

~€23 million

Segment revenues

2018

Proprietary Development

5 clinical candidates

1 program in preclinic

6 programs in discovery

Tremfya®

MOR106

MOR103

MOR202

tafasitamab

7

An ENFORCER™ antibody


Tafasitamab

tafasitamab

ENFORCER™

Enhanced Format for Cancer Eradication

Fc-engineered to address:

Increased recruitment of effector cells

Enhanced elimination of cancer cells

8

NHL – Non-Hodgkin lymphoma CLL – Chronic lymphotic leukemia ALL – Acute lymphoblastic leukemia

Assessing the clinical potential of our key proprietary asset


Tafasitamab Value Proposition

Chemo-free regimen aiming to improve

quality of life and outcome for patients

43% complete response rate

21.7 months duration of response

Data support overall survival outcome

ENFORCER™ goal to drive effective immune-mediated killing of malignant B cells

Demonstrated activity with lenalidomide

Single agent activity shown in other

forms of NHL, CLL & B-ALL

Readily combined with other agents

Opportunity to develop broadly

DLBCL Other B cell malignancies

9

Addressing different treatment approaches with L-MIND and B-MIND


Tafasitamab Clinical Trials in DLBCL

Tafasitamab + bendamustine

vs.

rituximab + bendamustine

Tafasitamab + lenalidomide

vs.

virtual lenalidomide-only

L-MIND B-MIND

Phase 2, open-label, single-arm trial

Virtual lenalidomide-only comparator arm

Compelling primary analysis data

Study ongoing with responding patients

Chemo-free regimen

Phase 2/3, randomized, multicenter trial

Biomarker subgroup: ~50% of patients

Futility analysis H2 2019

1. All-comers pass futility

Final data Q1 2020 (330 patients)

2. Only subgroup passes futility

Final data Q1 2021 (450 patients)

3. All-comers and subgroup fail futility

Study is futile

Different

combinations

Combination with an

immuno-modulatorCombination with a

chemotherapeutic

Different

modes of action

10

U.S. Commercial Strategy

Create U.S. hub to accelerate market uptake

Regulatory Strategy Framework

Pursue regulatory approval for tafasitamab in U.S. and EU

Setting a trajectory for greater value creation


Corporate Strategy

Clinical Development Direction

Seize tafasitamab opportunities to drive sustainable growth

Partnering

Maximize the value of our key asset

11

MorphoSys US Inc. located at Boston Harbor


MorphoSys U.S. Subsidiary

Located in the heart of the U.S. No. 1 Life

Sciences Cluster

Highly attractive to best-in-class talent

Strategic position for direct U.S. market access

12

L-MIND:

Breakthrough Therapy Designation granted in 2017

Close alignment with the FDA - minimizing risks

FDA guidance on reasonable ways forward

Planned BLA submission by end of 2019

Earliest approval mid-2020

B-MIND:

Pre-planned interim analysis in H2 2019

BLA – Biologics license agreement

Pursue regulatory approval for tafasitamab in U.S. and EU


Regulatory Strategy

FDA progress and next steps

EMA progress and next steps

L-MIND:

First interactions with national health authorities

Submitted request for scientific advice to EMA

13

Maximizing the value of tafasitamab with the best possible deal


Partnering Tafasitamab

Tafasitamab

Our flagship

asset

Strong interest based

on compelling clinical

data

Good chance for favorable regulatory

path in Europe – significant impact on

value of program

Focusing on exclusive

MorphoSys U.S. rights

In discussions with

interested parties

14

Key strategic directions for next wave of clinical trials


Clinical Development Direction

Position tafasitamab in competitive environment

Seize front-line DLBCL opportunities for tafasitamab

Go broad and deepin r/r DLBCL

Initiate development in other, non-DLBCL indications


Summary

Well on track with our goal to transform into

a fully integrated biopharmaceutical company

MorphoSys is set to become a key player

in the oncology field in the U.S.

Driving clinical assets development to enhance

proprietary pipeline product value

SUMMARY

Documents

Engineering the Medicines of Tomorrow · Compelling primary analysis data Study ongoing with responding patients Chemo-free regimen Phase 2/3, randomized, multicenter trial Biomarker